AbbVie
Trade AbbVie 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About ABBV
AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders, such as Parkinson's, metabolic, comprising thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions.
ABBV Key Statistics
Stock Snapshot
AbbVie(ABBV) stock is priced at $209.88, giving the company a market capitalization of 369.64B. It carries a P/E multiple of 88.52 and pays a dividend yield of 3.2%.
As of 2026-04-17, AbbVie(ABBV) stock has fluctuated between $209.20 and $209.88. The current price stands at $209.88, placing the stock +0.3% above today's low and 0.0% off the high.
The AbbVie(ABBV)'s current trading volume is 5.04K, compared to an average daily volume of 5.82M.
During the past year, AbbVie(ABBV) stock moved between $168.54 at its lowest and $244.81 at its peak.
During the past year, AbbVie(ABBV) stock moved between $168.54 at its lowest and $244.81 at its peak.
ABBV News
With AbbVie at around US$208 per share, this article looks at what the current price might imply and whether the stock may still offer value or if much of the u...
Abbvie (ABBV) announced an update on their ongoing clinical study. Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Di...
Abbvie (ABBV) announced an update on their ongoing clinical study. Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Di...
Analyst ratings
67%
of 33 ratingsMore ABBV News
Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Discover top-performing stock ideas and upgrade to a portfolio of mark...
Key Points AbbVie's weight-loss candidate recently posted strong results in a phase 1 study. However, this is an increasingly competitive area in which the co...
Abbvie (ABBV) announced an update on their ongoing clinical study. Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Di...
AbbVie (ABBV) is back in focus after releasing late breaking Phase 2 data for ELAHERE combined with carboplatin in recurrent platinum sensitive ovarian cancer,...
Evercore ISI lowered the firm’s price target on AbbVie (ABBV) to $232 from $233 and keeps an Outperform rating on the shares. The analyst adjusted estimates in...
AbbVie ABBV is set to report first-quarter 2026 results on April 29. While the company’s immunology portfolio will remain the primary focus, its neuroscience se...
The company said, “This morning, we announced the termination of our development agreement with AbbVie (ABBV). While this represents the close of an important c...
People also own
Similar Marketcap
This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.
Popular Stocks
This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset
Newly Listed
This list is generated by showing companies that recently went public.